More than 8 million people in the U.S. take blood thinners to prevent dangerous clots. At the same time, the drugs are ...

TIGERTRIEVER (TM) 13 is the first device shown to meet safety and effectiveness endpoints for restoring blood flow in smaller but critical areas of the brain, accounting for almost 50% of all ischemic ...

Global phase 3 OCEANIC-STROKE randomized 12,327 patients to asundexian 50 mg daily vs placebo on background antiplatelets, with follow-up to 31 months. Treatment effects were consistent across TOAST ...

NEW ORLEANS -- IV tenecteplase (TNKase) could be beneficial as far out as 24 hours after stroke onset in people not getting mechanical thrombectomy, the OPTION trial showed.

With the study adding to a mix of conflicting trial results, it’s not yet time to update guidelines, Shyam Prabhakaran says.

Dementia risk rises dramatically in people with CAA, a condition where amyloid builds up in brain blood vessels, even when no stroke occurs.

For patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack, asundexian, a factor XIa inhibitor, reduced risk for secondary stroke with no excess risk for any bleeding vs ...

Experts at ISC 2026 highlighted growing evidence that GLP-1 receptor agonists may reduce stroke risk and support brain health ...

Clinical trial results indicate a protein, rFVIIa, may benefit certain stroke patients when administered quickly, with a focus on acute intracerebral hemorrhage treatments.

Results from the CHOICE-2 trial show a 15% absolute increase in excellent functional outcomes with intra-arterial alteplase ...

The factor XIa inhibitor asundexian reduced recurrent ischemic stroke without increasing major or minor bleeding in patients ...

A new study connects dairy to some benefits for your heart—here's what to know.